Michael Hale Reutershan

USPTO Granted Patents = 20 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 17 (Patent Applications = 16)

Average Co-Inventor Count = 11.6

ph-index = 3

Forward Citations = 74(Granted Patents)

Location History:

Brookline, MA (US) (2013 - 2017)
Boston, MA (US) (2019)
Brighton, MA (US) (2014 - 2024)

Company Filing History:

20 out of 2,405

Merck Sharp + Dohme Corp.

Msd International Gmbh

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

20 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12441730 - PRMT5 inhibitors (2025-10-14),

2. 12173026 - PRMT5 inhibitors (2024-12-24),

3. 11993602 - PRMT5 inhibitors (2024-05-28),

4. 11981701 - PRMT5 inhibitors (2024-05-14),

5. 11098059 - PRMT5 inhibitors (2021-08-24),

6. 10947234 - PRMT5 inhibitors (2021-03-16),

7. 10508108 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-12-17),

8. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),

9. 9682978 - 2,6,7 substituted purines as HDM2 inhibitors (2017-06-20),

10. 9637493 - Substituted pyrrolopyrimidines as HDM2 inhibitors (2017-05-02),

11. 9598405 - Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors (2017-03-21),

12. 9586931 - Triazolyl derivatives as Syk inhibitors (2017-03-07),

13. 9540377 - 2,6,7,8 substituted purines as HDM2 inhibitors (2017-01-10),

14. 9487504 - Imidazolyl analogs as syk inhibitors (2016-11-08),

15. 9376418 - Substituted pyridine spleen tyrosine kinase (SYK) inhibitors (2016-06-28),

Title: Michael Hale Reutershan: Innovating PRMT5 Inhibitors

Introduction: Michael Hale Reutershan, based in Brighton, MA, is a prolific inventor with a remarkable portfolio of 19 patents. His contributions to the field of pharmaceuticals, particularly in developing PRMT5 inhibitors, have significant implications for treating various medical conditions, including cancer and sickle cell disease.

Latest Patents: Reutershan's latest inventions focus on a class of compounds known as PRMT5 inhibitors. These compounds are identified by Formula (I) and include pharmaceutically acceptable salts, esters, and prodrugs. His groundbreaking work outlines methods for synthesizing these compounds, as well as their potential applications in treating cancer, sickle cell conditions, and hereditary persistence of fetal hemoglobin (HPFH) mutations. This innovation highlights his commitment to advancing therapeutic options for patients suffering from challenging health issues.

Career Highlights: Throughout his career, Michael Hale Reutershan has been associated with prominent organizations in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Merck Canada Inc. His work has been pivotal in the advancement of innovative treatments and has garnered him recognition as a leading inventor in his field.

Collaborations: Reutershan has collaborated with notable colleagues such as Michelle R Machacek and Michael D Altman. These partnerships have, undoubtedly, contributed to the successful development and optimization of his patented inventions.

Conclusion: Michael Hale Reutershan's dedication to innovation in the pharmaceutical landscape is evident through his extensive patent portfolio and collaborative efforts. His advancements in PRMT5 inhibitors not only underscore his role as a significant inventor but also pave the way for potential breakthroughs in treating various diseases.

This text is generated by artificial intelligence and may not be accurate.